Gilead Sciences, Inc. is providing this letter in response to your unsolicited request for medical information. It is not promotional. It is intended for a US audience 18 years or older.

GILEAD | Medical Information

VEMLIDY® (tenofovir alafenamide)

What should I do if I miss a dose?

This information is provided in response to your question. It is not treatment advice on how to use VEMLIDY. Please discuss this question and others you have about your medical condition or treatment with your healthcare provider.

Download the **VEMLIDY Patient Information** for more details, including approved use(s) and important warnings. **https://www.gilead.com/-/media/files/pdfs/medicines/liver-disease/vemlidy/vemlidy_pi.pdf**

The short answer[1,2]

Take VEMLIDY exactly as your healthcare provider tells you to take it.

Take one tablet every day with food.



Do not change your dose or stop taking VEMLIDY without asking your healthcare provider.

If a dose is missed and less than 18 hours have passed from the time it is usually taken, take the medicine as soon as possible and contact your healthcare provider.

If more than 18 hours have passed: Skip the dose and take your next dose at the normal time. Do not take two doses. Contact your healthcare provider.



If you vomit within 1 hour after taking VEMLIDY, **take another tablet**.

Approved for Use on 03 Nov 2026

If you vomit after 1 hour or more, **you do not need to take another tablet.**

What is the most important information I should know about VEMLIDY?[1]

Some medications have important warnings that are designed to alert you of serious or life-threatening risks that come with taking the medication.

VEMLIDY has an important warning for: **Worsening of hepatitis B virus (HBV) infection. Your HBV infection may get worse (flare-up) if you take VEMLIDY and then stop taking it. A "flare-up" is when your HBV infection suddenly returns in a worse way than before.**

- Do not run out of VEMLIDY. Refill your prescription or talk to your healthcare provider before your VEMLIDY is all gone.
- Do not stop taking VEMLIDY without first talking to your healthcare provider.
- If you stop taking VEMLIDY, your healthcare provider will need to check your health often and do blood tests regularly for several months to check your liver. Tell your healthcare provider about any new or unusual symptoms you may have after you stop taking VEMLIDY.

What should I know about VEMLIDY?[1]



VEMLIDY is a medicine used to treat chronic (long-lasting) hepatitis B virus (HBV) in adults and children 6 years of age and older who weigh at least 55 pounds (25kg) and have stable (compensated) liver disease.


VEMLIDY may lower the amount of hepatitis B virus (HBV) in your body.

VEMLIDY may improve the condition of your liver.

It is not known if VEMLIDY is safe and effective in children with chronic HBV infection who are under 6 years old or weigh less than 55 pounds (25 kg).

Approved for Use on 03 Nov 2026

How should I take VEMLIDY?[1]



- Take VEMLIDY exactly as your healthcare provider tells you to take it.
- Take one tablet every day with food. If you are on dialysis, take your dose after dialysis on those days.
- **Do not** change your dose or stop taking VEMLIDY without asking your healthcare provider.

Stay under your healthcare provider's care when taking VEMLIDY.

- If you take too much VEMLIDY, call your healthcare provider or go to the hospital emergency room right away.
- **Do not miss** a dose of VEMLIDY. Take VEMLIDY exactly as your healthcare provider tells you.
- When your VEMLIDY supply starts to run low, get more from your healthcare provider or pharmacy. This is very important because your HBV infection may get worse (flare-up) if you stop taking VEMLIDY.

Glossary

Chronic: long-lasting.

Compensated: stable liver disease.

Dialysis: a procedure that takes out waste products and extra fluid from the blood when the kidneys are not working properly.

Flare: disease suddenly becomes worse.

Hepatitis B Virus (HBV): a type of virus (HBV) that can cause serious liver infection.

Reference

1. Enclosed. Gilead Sciences Inc, VEMLIDY® (tenofovir alafenamide) tablets, for oral use. U.S. Prescribing Information. Foster City, CA.

2. Vemlidy, Gilead Sciences Ltd. Vemlidy 25 mg Film Coated Tablets. Summary of Product Characteristics (SmPC). Updated: May. 2018.

Approved for Use on 03 Nov 2026

More information about VEMLIDY

If you would like more detailed information about VEMLIDY, please visit: https://www.gilead.com/-/media/files/pdfs/medicines/liver-disease/vemlidy/vemlidy_pi.pdf.

This is the US FDA-approved Prescribing Information, including the Patient Labeling, for VEMLIDY. It will tell you about the uses, warnings, and other important safety information about VEMLIDY.

Important note

Gilead Sciences, Inc. is providing this letter in response to your unsolicited request for medical information. Some of the information included in this letter may not be covered in the US FDA-approved Prescribing Information for VEMLIDY. Gilead Sciences, Inc. does not intend this letter to be used as medical advice and does not promote use of VEMLIDY in a way that has not been approved by the FDA. Please discuss this question and others you may have about your medical condition or treatment with your healthcare provider.

Follow-Up

For any additional questions, please contact Gilead Medical Information at:
☎1-866-MEDI-GSI (1-866-633-4474) or https://www.patient.askgileadmedical.com/

Reporting side effects

Please report all adverse events to:
Gilead Global Patient Safety ☎ 1-800-445-3235, option 3 or
www.gilead.com/utility/contact/report-an-adverse-event

FDA MedWatch Program by ☎ 1-800-FDA-1088 or MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or 8 www.accessdata.fda.gov/scripts/medwatch

Data Privacy

The Medical Information service at Gilead Sciences may collect, store, and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.

It may be necessary for us to share your information with Gilead's affiliates, business partners, service providers, and regulatory authorities located in countries besides your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement (www.gilead.com/privacy-statements) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact privacy@gilead.com.

VEMLIDY, GILEAD, and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or its related companies.
© 2025 Gilead Sciences, Inc.

Approved for Use on 03 Nov 2026